Immunitybio Inc (IBRX)

Currency in USD
6.625
+0.365(+5.83%)
Real-time Data·
IBRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.1206.660
52 wk Range
1.95012.430
Key Statistics
Prev. Close
6.26
Open
6.22
Day's Range
6.12-6.66
52 wk Range
1.95-12.43
Volume
4.19M
Average Volume (3m)
12.72M
1-Year Change
215.4762%
Book Value / Share
-1.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.250
Upside
+115.09%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Immunitybio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.250
(+115.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy15.00+126.62%-Maintain15-10-2026
Jefferies
Buy14.00+111.51%12.00Maintain14-10-2026
BTIG
Buy13.00+96.40%-Maintain24-03-2026
BTIG
Buy13.00+96.40%-New Coverage11-03-2026
Piper Sandler
Buy12.00+81.30%7.00Maintain04-03-2026

Immunitybio Inc Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of -$0.06 beat forecast of -$0.11; revenue hit $38.28M, exceeding $35.99M estimate by 6.36%
  • Stock surged 32.76% to $11.55 in pre-market trading; full-year revenue jumped 700% to $113M driven by ANKTIVA adoption
  • Net loss reduced 15% year-over-year to $351.4M; sequential quarterly growth demonstrated strong commercial momentum
  • 2026 guidance projects EPS of -$0.07 per quarter; revenue forecasts show $51.36M for Q2 and $60.01M for Q3
  • CEO emphasized transformational progress with ANKTIVA's FDA approval and international expansion plans underway
Last Updated: 04-03-2026, 05:10 am
Read Full Transcript

Earnings

Latest Release
09-11-2026
EPS / Forecast
-0.18 / -0.08
Revenue / Forecast
48.84M / 59.23M
EPS Revisions
Last 90 days

IBRX Income Statement

Compare IBRX to Peers and Sector

Metrics to compare
IBRX
Peers
Sector
Relationship
P/E Ratio
−6.0x−1.7x−0.2x
PEG Ratio
0.04−0.270.00
Price/Book
−5.8x2.3x2.6x
Price / LTM Sales
36.5x7.5x2.7x
Upside (Analyst Target)
122.3%132.8%68.5%
Fair Value Upside
Unlock7.3%11.5%Unlock

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
110.63M10.40%661.55M
Other Institutional Investors
460.45M43.28%2.75B
Public Companies & Retail Investors
492.75M46.32%2.95B
Total
1.06B100.00%6.36B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
California Capital Equity, LLC24.35%25,89,95,03215,48,790
NantWorks, LLC9.26%9,85,35,2535,89,241

FAQ

What Is the Immunitybio Inc (IBRX) Share Price Today?

The Immunitybio Inc share price today is 6.625.

What is the current Immunitybio Inc (IBRX) share price and day range?

As of 18-11-2026, the Immunitybio Inc share price is 6.625, with a previous close of 6.260. The share price has ranged from 6.120 to 6.660 today, while the 52-week range spans from 1.950 to 12.430.

What Is the Immunitybio Inc Market Cap?

As of today, Immunitybio Inc market cap is 7.040B.

What Is the Immunitybio Inc (IBRX) Share Price Target?

The average 12-month share price target for Immunitybio Inc is 14.250, with a high estimate of 16 and a low estimate of 12. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +115.09% Upside potential.

What Is Immunitybio Inc's Earnings Per Share (TTM)?

The Immunitybio Inc EPS (TTM) is -1.08.

When Is the Next Immunitybio Inc Earnings Date?

Immunitybio Inc will release its next earnings report on 02-03-2027.

From a Technical Analysis Perspective, Is IBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Immunitybio Inc Trade On?

Immunitybio Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunitybio Inc?

The stock symbol for Immunitybio Inc is "IBRX."

How Many Times Has Immunitybio Inc Stock Split?

Immunitybio Inc has split 0 times.

How Many Employees Does Immunitybio Inc Have?

Immunitybio Inc has 688 employees.

What Is the IBRX Premarket Price?

IBRX's last pre-market stock price is 6.290. The pre-market share volume is 84,350.000, and the stock has changed by 0.030, or 0.480%.

What Is the IBRX After Hours Price?

IBRX's last after hours stock price is 6.280, the stock has changed by 0.020, or 0.320%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.